I’m not sure upon what basis that argument can be made? There are plenty of successful development stage biotechs that don’t have this long and enduring list of problems.
I also believe Boynton and Bosch are getting short changed when that myth of the heroic LP is advanced.
NWBO is more the story of better to be lucky than good. The more I think about this professionally, the more I feel like I was skating on thin ice and just lucky not to fall in. Almost by miracle.